spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  alpha-Gal 

 HSMN NewsFeed - 19 Dec 2025
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Jul 2020
FDA Clears First Blood Test for Identifying a Novel Allergic Sensitization to Red Meat
Diagnostics FDA
 HSMN NewsFeed - 19 Dec 2019
Protalix BioTherapeutics Adds Two Accomplished Biopharmaceutical Executives to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Nov 2019
Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of pegunigalsidase alfa for the Treatment of Fabry Disease in the United States
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Dec 2017
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Oct 2015
Amicus Therapeutics Provides U.S. Regulatory Update for Migalastat Monotherapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jun 2015
Amicus Therapeutics Submits Marketing Authorization Application (MAA) for Full Approval of Fabry Monotherapy Galafold(TM) (Migalastat) in European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Aug 2014
Amicus Therapeutics Announces Positive Phase 3 Data From Fabry Monotherapy Study 012
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2014
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
Biopharmaceuticals
 HSMN NewsFeed - 29 Apr 2013
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Jan 2013
NewLink Genetics Appoints Mr. Brian Wiley as Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2012
Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO(TM) (taliglucerase alfa)
Biopharmaceuticals
 HSMN NewsFeed - 25 Feb 2011
FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application
Biopharmaceuticals
 HSMN NewsFeed - 24 Feb 2010
Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals
 HSMN NewsFeed - 22 Dec 2009
Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement to Develop and Commercialize Amigal(TM), Plicera(TM) and At2220
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Nov 2007
Shire Expands its Human Genetic Therapies Pipeline Through In-Licensing Agreement With Amicus Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 22 May 2007
Shire Human Genetic Therapies AB Signs Exclusive Marketing and Distribution Deal With Samaritan to Launch REPLAGAL for Fabry Disease in Greece and Cyprus
Biopharmaceuticals Distribution
Return to NewsFeed  

 Additional items found! 5

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 5 additional stories matching:
alpha-Gal
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!